S & D HARPER LIMITED

Financial Health Score: B-

Explanation: S & D Harper Limited possesses a robust skeletal structure—demonstrated by strong net assets and a long-standing market presence since 1982. However, the business is currently suffering from acute "financial anemia." The cash reserves are dangerously low, and significant liquidity is trapped in interest-free loans to directors and related parties. While the company is not insolvent, its vital fluid (cash) is not circulating properly, leaving it vulnerable to sudden financial shocks.

Key Vital Signs

• Net Assets (Skeletal Strength): £1,483,513 (Up from £1,468,296 in 2023).
  • Interpretation: The business has a solid foundation of owned assets, indicating long-term viability and a strong net worth.
• Working Capital (Daily Energy): £149,985 (Down from £228,555 in 2023).
  • Interpretation: The buffer between short-term assets and short-term debts is constricting. The business has less financial energy to fund its day-to-day operations comfortably.
• Current Ratio (Immune System Strength): 1.13 (£1,269,569 / £1,119,584).
  • Interpretation: A ratio of 1.13 means the company can just barely cover its short-term debts with its short-term assets. This is a marginal reading—healthy is typically above 1.3.
• Cash at Bank (Blood Pressure): £1,767 (Unchanged from 2023).
  • Interpretation: Dangerously low. For a company with over £2.8 million in total assets, holding less than £2,000 in cash is a symptom of severe financial anemia.
• Total Liabilities (Cholesterol): £1,358,207 (Current + Long-term + Provisions).
  • Interpretation: Total debts are high, and a significant portion is secured by fixed and floating charges over the company's properties and assets, placing a heavy burden on the company's vital organs.

Diagnosis (Symptoms Analysis)

1. Severe Financial Anemia (Critical Cash Depletion) The most alarming symptom in this assessment is the cash position. A cash balance of £1,767 is practically flatlining for a business of this scale. The company is surviving not on its own cash reserves, but by relying heavily on creditor payment terms (Trade Creditors at £626k) and short-term overdraft facilities (£349k). This lack of liquid reserves means the business has no immune defense against unexpected costs or sudden drops in revenue.

2. Poor Circulation (Blocked Arteries) The balance sheet reveals significant blockages in the company's financial circulation. The business is owed £71,558 by its directors and £183,154 by other related parties. These loans are interest-free with no fixed terms of repayment. While the directors eventually repaid some of the prior year's balance (£52,300), they immediately borrowed more (£69,970). This represents a substantial amount of vital capital that is trapped outside the business, depriving the operating core of the liquidity it desperately needs.

3. Muscle Growth (Capital Investment) Despite the cash constraints, the company invested £238,736 in new plant and machinery in 2024. While investing in operational "muscle" is generally a sign of confidence and long-term planning, funding this expansion through short-term finance leases and overdrafts while holding minimal cash is a risky treatment plan. It has contributed to the tightening of the working capital position.

4. Inventory Clearance (Dieting) Stock levels dropped from £1,010,427 to £843,857. While converting stock to cash is usually a healthy process, the cash hasn't actually materialized in the bank account (cash remained at £1,767). This implies the cash generated from selling stock was immediately swallowed up by capital expenditures, repaying trade creditors, or increased borrowing.

Prognosis

The long-term prognosis for S & D Harper Limited is stable but guarded. The company's underlying health—its property assets, retained earnings, and over 40 years of trading history—provides a strong constitution. However, the short-term outlook is fragile. The business is highly susceptible to a liquidity crisis. If trade creditors tighten their terms, or if the bank calls in the overdraft, the company could quickly find itself in respiratory distress.

Recommendations (Prescription for Financial Wellness)

1. Clear the Blocked Arteries (Call in Related Party Loans): The most immediate treatment is to recover the £254,712 currently locked in director and related-party loans. As these are interest-free and unsecured, they should be repaid to the business to replenish the cash reserves and reduce reliance on expensive bank overdrafts.
2. Blood Transfusion (Cash Flow Management): Implement stricter working capital controls. Actively chase trade debtors (£123,198) to accelerate cash collection. Even a slight improvement in debtor days could significantly boost the cash position.
3. Restructure the Medication (Debt Refinancing): With £349,198 in short-term bank loans and overdrafts, the company is relying on short-term, potentially high-interest medication to cure long-term needs. Consider refinancing a portion of this debt into a long-term loan, which will ease the pressure on daily cash flow and improve the current ratio.
4. Monitor Vital Signs Closely: The directors must prioritize cash flow forecasting. With a current ratio of 1.13 and minimal cash, there is zero margin for error. Regular monthly check-ups of the cash position are essential to prevent a sudden financial cardiac arrest.